The Perimenopause Context Perimenopause represents a complex biological and psychological transition currently affecting 1.55 billion women globally
These tests are not standard and are only done when necessary for medical, legal, or research needs
This includes variations between the type of GLP-1 agent, dose, duration of therapy or underlying patient phenotype such as body mass and metabolic rate, patients age, muscle activity, previous toxin treatments, and/or dosage
The next section splits these mechanisms into two practical groups: FDA-approved GLP-1 drugs available only by prescription, such as semaglutide and tirzepatide, and non-prescription peptides that work through growth-hormone stimulation or fat-cell targeting instead, such as CJC-1295 and AOD-9604
see the peptide reconstitution guide